141 related articles for article (PubMed ID: 36131603)
1. Effect of capmatinib on the pharmacokinetics of substrates of CYP3A (midazolam) and CYP1A2 (caffeine) in patients with MET-dysregulated solid tumours.
Chen X; Isambert N; López-López R; Giovannini M; Pognan N; Kapoor S; Quinlan M; You B; Cui X; Rahmanzadeh G; Mau-Sorensen M
Br J Clin Pharmacol; 2023 Mar; 89(3):1046-1055. PubMed ID: 36131603
[TBL] [Abstract][Full Text] [Related]
2. Interaction profile of armodafinil with medications metabolized by cytochrome P450 enzymes 1A2, 3A4 and 2C19 in healthy subjects.
Darwish M; Kirby M; Robertson P; Hellriegel ET
Clin Pharmacokinet; 2008; 47(1):61-74. PubMed ID: 18076219
[TBL] [Abstract][Full Text] [Related]
3. Phase I study to assess the effect of adavosertib (AZD1775) on the pharmacokinetics of substrates of CYP1A2, CYP2C19, and CYP3A in patients with advanced solid tumors.
Någård M; Ah-See ML; Strauss J; Wise-Draper T; Safran HP; Nadeau L; Edenfield WJ; Lewis LD; Ottesen LH; Li Y; Mugundu GM
Cancer Chemother Pharmacol; 2023 Sep; 92(3):193-203. PubMed ID: 37394627
[TBL] [Abstract][Full Text] [Related]
4. Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with Cancer.
Turner PK; Hall SD; Chapman SC; Rehmel JL; Royalty JE; Guo Y; Kulanthaivel P
Drug Metab Dispos; 2020 Sep; 48(9):796-803. PubMed ID: 32581049
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic drug interactions between clobazam and drugs metabolized by cytochrome P450 isoenzymes.
Walzer M; Bekersky I; Blum RA; Tolbert D
Pharmacotherapy; 2012 Apr; 32(4):340-53. PubMed ID: 22422635
[TBL] [Abstract][Full Text] [Related]
6. An interaction between the cytochrome P450 probe substrates chlorzoxazone (CYP2E1) and midazolam (CYP3A).
Palmer JL; Scott RJ; Gibson A; Dickins M; Pleasance S
Br J Clin Pharmacol; 2001 Nov; 52(5):555-61. PubMed ID: 11736864
[TBL] [Abstract][Full Text] [Related]
7. Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam.
Britz H; Hanke N; Volz AK; Spigset O; Schwab M; Eissing T; Wendl T; Frechen S; Lehr T
CPT Pharmacometrics Syst Pharmacol; 2019 May; 8(5):296-307. PubMed ID: 30762305
[TBL] [Abstract][Full Text] [Related]
8. Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults.
Armani S; Ting L; Sauter N; Darstein C; Tripathi AP; Wang L; Zhu B; Gu H; Chun DY; Einolf HJ; Kulkarni S
Clin Drug Investig; 2017 May; 37(5):465-472. PubMed ID: 28155129
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A.
Turpault S; Brian W; Van Horn R; Santoni A; Poitiers F; Donazzolo Y; Boulenc X
Br J Clin Pharmacol; 2009 Dec; 68(6):928-35. PubMed ID: 20002088
[TBL] [Abstract][Full Text] [Related]
10. A clinical study to assess CYP1A2 and CYP3A4 induction by AZD7325, a selective GABA(A) receptor modulator - an in vitro and in vivo comparison.
Zhou D; Sunzel M; Ribadeneira MD; Smith MA; Desai D; Lin J; Grimm SW
Br J Clin Pharmacol; 2012 Jul; 74(1):98-108. PubMed ID: 22122233
[TBL] [Abstract][Full Text] [Related]
11. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the "Cooperstown cocktail".
Streetman DS; Bleakley JF; Kim JS; Nafziger AN; Leeder JS; Gaedigk A; Gotschall R; Kearns GL; Bertino JS
Clin Pharmacol Ther; 2000 Oct; 68(4):375-83. PubMed ID: 11061577
[TBL] [Abstract][Full Text] [Related]
12. Eltrombopag, an oral thrombopoietin receptor agonist, has no impact on the pharmacokinetic profile of probe drugs for cytochrome P450 isoenzymes CYP3A4, CYP1A2, CYP2C9 and CYP2C19 in healthy men: a cocktail analysis.
Jenkins J; Williams D; Deng Y; Collins DA; Kitchen VS
Eur J Clin Pharmacol; 2010 Jan; 66(1):67-76. PubMed ID: 19756558
[TBL] [Abstract][Full Text] [Related]
13. Effects of Upadacitinib Coadministration on the Pharmacokinetics of Sensitive Cytochrome P450 Probe Substrates: A Study With the Modified Cooperstown 5+1 Cocktail.
Mohamed MF; Feng T; Enejosa JV; Fisniku O; Othman AA
J Clin Pharmacol; 2020 Jan; 60(1):86-95. PubMed ID: 31378969
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of Drug-Drug Interaction Potential of Enarodustat (JTZ-951) Using a Cytochrome P450 Probe Cocktail.
Pai SM; Yamada H; Murata H
Clin Pharmacol Drug Dev; 2023 Jul; 12(7):667-682. PubMed ID: 37269147
[TBL] [Abstract][Full Text] [Related]
15. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo.
Gorski JC; Huang SM; Pinto A; Hamman MA; Hilligoss JK; Zaheer NA; Desai M; Miller M; Hall SD
Clin Pharmacol Ther; 2004 Jan; 75(1):89-100. PubMed ID: 14749695
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic Protein Drug Interaction Potential in Subjects With Psoriasis: An Assessment Based on Population Pharmacokinetic Analyses of Sensitive Cytochrome P450 Probe Substrates.
Sathe AG; Othman AA; Mohamed MF
J Clin Pharmacol; 2021 Mar; 61(3):307-318. PubMed ID: 32960975
[TBL] [Abstract][Full Text] [Related]
17. The effects of St John's wort (Hypericum perforatum) on human cytochrome P450 activity.
Wang Z; Gorski JC; Hamman MA; Huang SM; Lesko LJ; Hall SD
Clin Pharmacol Ther; 2001 Oct; 70(4):317-26. PubMed ID: 11673747
[TBL] [Abstract][Full Text] [Related]
18. Lisdexamfetamine Dimesylate Effects on the Pharmacokinetics of Cytochrome P450 Substrates in Healthy Adults in an Open-Label, Randomized, Crossover Study.
Ermer J; Corcoran M; Martin P
Drugs R D; 2015 Jun; 15(2):175-85. PubMed ID: 25862215
[TBL] [Abstract][Full Text] [Related]
19. Effect of capmatinib on the pharmacokinetics of digoxin and rosuvastatin administered as a 2-drug cocktail in patients with MET-dysregulated advanced solid tumours: A phase I, multicentre, open-label, single-sequence drug-drug interaction study.
Grande E; Giovannini M; Marriere E; Pultar P; Quinlan M; Chen X; Rahmanzadeh G; Curigliano G; Cui X
Br J Clin Pharmacol; 2021 Jul; 87(7):2867-2878. PubMed ID: 33300203
[TBL] [Abstract][Full Text] [Related]
20. Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis.
Khatri A; Cheng L; Camez A; Ignatenko S; Pang Y; Othman AA
Clin Pharmacokinet; 2019 Jun; 58(6):805-814. PubMed ID: 30574672
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
